Intercure (INCR) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intercure (INCR) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 37.5% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -85.8% for INCR. Intercure is the larger company by market cap ($77.6 million vs $73.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | ONCY |
|---|---|---|
| Share price | $5.17 | $0.557 |
| Market cap | $77.57M | $73.03M |
| 1-day change | +2.99% | +2.31% |
| YTD return | +10.55% | -37.43% |
| 1-year return | -37.52% | -57.47% |
| 5-year return | -85.81% | -75.48% |
| EPS (TTM) | $-0.95 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $1.32 |
| 52-week low | $3.40 | $0.525 |
| Distance from 52-week high | -38.45% | -57.80% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +645.06% |
| Average volume | 21.73K | 1.08M |
| Shares outstanding | 15.00M | 131.12M |
| Employees | 285 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed ONCY by 20.0 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
INCR vs ONCY FAQ
Which is bigger, Intercure or Oncolytics Biotech?
Intercure (INCR) is larger, with a market capitalization of $77.57M compared with $73.03M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, INCR or ONCY?
INCR returned -37.52% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.